Zynerba's Therapeutics And Data Lack Conviction

Summary

There are no FDA-approved therapies for Fragile X Syndrome.

ZYN002 appears to have demonstrated meaningful and overwhelming efficacy data in a phase 2 trial.

There are, however, disclaimers and reasons for caution surrounding the drug and its data.

We believe it is best to avoid buying shares in Zynerba and urge investors to seek opportunities elsewhere.

Zynerba Pharmaceuticals (ZYNE) is developing CBD therapeutics for neuropsychiatric conditions. Their pipeline looks like this:

Source: Zynerba's product pipeline

Well, actually, it doesn't anymore. The company recently announced they are only pursuing indications with ZYN002 after their patch failed a phase 1 study. They've just been reluctant to update it, I guess.

READ FULL ARTICLE HERE